| Literature DB >> 30420937 |
Hoa Thi Le1, Kyu H Park2, Woong Jung3, Hyung Soon Park2, Tae Woo Kim1.
Abstract
We developed a new method for MALDI-TOF MS detection of N-glycans derived from human serum. The synergistic combination of microwave-assisted Girard T derivatization, solid-phase extraction desalting, and an ionic liquid matrix (2, 5-dihydroxybenzoic acid/aniline) (GT-SPE-DHB/An) allowed of more sensitive N-glycans detection than a conventional ionic liquid matrix in MALDI-TOF MS. The superior sensitivity of our method was confirmed by the number of assigned N-glycans in 900-2,000 m/z range. Using our GT-SPE-DHB/An method, we were successfully able to assign 31 glycans. However, with the established method, i.e., DHB/An method, only 15 glycans were assigned. To the best of our knowledge, this GT-SPE-DHB/An method is the first to combine cationic derivatization of N-glycan and ionic liquid matrix for N-glycan analysis in MALDI-TOF MS.Entities:
Year: 2018 PMID: 30420937 PMCID: PMC6215560 DOI: 10.1155/2018/7832987
Source DB: PubMed Journal: J Anal Methods Chem ISSN: 2090-8873 Impact factor: 2.193
Scheme 1Glycan derivatization chemistry and ionic liquid matrix. (a) Hydrazide reaction of Girard reagents with a hexose. GT = Girard's reagent T (tetramethyl ammonium); GP = Girard's reagent P (pyridium). (b) ILM formation of 2, 5-dihydroxybenzoic acid and aniline.
Scheme 2Workflow of GT-SPE-DHB/An method for N-glycan analysis in MALDI-TOF MS.
Red-white conditional formatting table between three variables (matrix, base, and tagging reagent) and the MALDI R/N ratio of maltohexaose or its Girard derivatives. ND = not detected. Color scale: deeper red highlighted cells correspond to higher R/N ratio.
| Derivatization | Matrix | Base | ||||
|---|---|---|---|---|---|---|
| An | MI | TMG | TEA | Pyr | ||
| Girard's T | DHB | 245 | 5 | ND | 63 | 224 |
| CHCA | 335 | 3,970 | 1,317 | 4,972 | 62 | |
|
| ND | ND | ND | ND | ND | |
|
| ||||||
| Girard's P | DHB | 99 | ND | ND | 36 | 9 |
| CHCA | 2,823 | 4,423 | 15 | 2,842 | 43 | |
|
| ND | 4 | ND | ND | ND | |
|
| ||||||
| Nonderivatization | DHB | 18 | ND | ND | ND | 248 |
| CHCA | 621 | 4,421 | 10 | 4,974 | 354 | |
|
| ND | ND | ND | ND | ND | |
Condition optimization. MS intensity for each glycan at three different conditions and the enhancement factors (EFs).
| Glycan no. | MS intensity | Enhancement Factor | |||
|---|---|---|---|---|---|
| Condition 1 MW | Condition 2 SPE | Condition 3 MW + SPE | Con 3/Con 1 w/or w/o SPE | Con 3/Con 2 w/or w/o MW | |
| IS | 29738 | 299037 | 682825 | 23.0 | 2.3 |
| G5 | 5991 | 72493 | 122582 | 20.5 | 1.7 |
| G8 | 2463 | 9714 | 12278 | 5.0 | 1.3 |
| G10 | 5328 | 56814 | 97849 | 18.4 | 1.7 |
| G14 | 11482 | 91319 | 227387 | 19.8 | 2.5 |
| G15 | 2493 | 11139 | 15844 | 6.4 | 1.4 |
| G17 | 2604 | 10991 | 24068 | 9.2 | 2.2 |
| G20 | 2377 | 31626 | 76822 | 32.3 | 2.4 |
| G21 | 13829 | 93595 | 270122 | 19.5 | 2.9 |
| G23 | 2372 | 20225 | 45111 | 19.0 | 2.2 |
| G25 | 2806 | 20863 | 39855 | 14.2 | 1.9 |
| G27 | 5192 | 32241 | 83983 | 16.2 | 2.6 |
| G28 | 3974 | 22301 | 57710 | 14.5 | 2.6 |
| G30 | 2777 | 20591 | 40422 | 14.6 | 2.0 |
| Ave ± STD | 16.6 ± 7.0 | 2.1 ± 0.5 | |||
We calculated the EFs for the glycans, which were commonly assigned at the three conditions.
Figure 1MALDI-TOF MS spectra of (a) GT derivatized N-glycans obtained from the optimized GT-SPE-DHB/An method and (b) N-glycans obtained from DHB/An method.
MALDI peak intensity table of the assigned glycans in 900–2,000 m/z range.
| Glycan ID no. | MS intensity | Ranking | Group | EF | |
|---|---|---|---|---|---|
| Method 1 = GT-SPE-DHB/An | Method 2 = DHB/An | ||||
| G1 | 22,523 | 7,904 | 19 | 2 | 2.8 |
| G2 | 14,247 | — | 24 | 3 | — |
| G3 | 8,621 | — | 31 | 3 | — |
| G4 | 13,752 | — | 25 | 3 | — |
| G5 | 556,350 | 25,650 | 2 | 1 | 21.7 |
| G6 | 12,904 | — | 27 | 3 | — |
| G7 | 23,418 | — | 16 | 2 | — |
| G8 | 23,395 | — | 17 | 2 | — |
| G9 | 11,284 | — | 28 | 3 | — |
| G10 | 428,229 | 18,631 | 4 | 1 | 23.0 |
| G11 | 8,857 | — | 30 | 3 | — |
| G12 | 14,250 | — | 23 | 3 | — |
| G13 | 38,460 | — | 13 | 2 | — |
| G14 | 495,759 | 33,830 | 3 | 1 | 14.7 |
| G15 | 38,971 | 9,724 | 12 | 2 | 4.0 |
| G16 | 17,100 | 6,714 | 22 | 3 | 2.5 |
| G17 | 78,584 | 8,961 | 9 | 1 | 8.8 |
| G18 | 13,420 | — | 26 | 3 | — |
| G19 | 18,481 | — | 20 | 2 | — |
| G20 | 50,126 | — | 11 | 2 | — |
| G21 | 601,498 | 52,609 | 1 | 1 | 11.4 |
| G22 | 30,297 | 10,260 | 15 | 2 | 3.0 |
| G23 | 81,931 | 11,867 | 8 | 1 | 6.9 |
| G24 | 22,814 | 8,421 | 18 | 2 | 2.7 |
| G25 | 89,870 | 10,485 | 7 | 1 | 8.6 |
| G26 | 18,283 | — | 21 | 3 | — |
| G27 | 205,902 | 23,231 | 5 | 1 | 8.9 |
| G28 | 105,748 | 14,170 | 6 | 1 | 7.5 |
| G29 | 9,020 | — | 29 | 3 | — |
| G30 | 52,571 | 8,941 | 10 | 1 | 5.9 |
| G31 | 30,831 | — | 14 | 2 | — |
| Ave ± STD | 8.8 ± 6.5 | ||||
Method 1 = GT-SPE-DHB/An method; Method 2 = DHB/An method. Group 1 = ranking scale from 1 to 10; Group 2 = from 11 to 20; Group 3 = from 21 to 31. EF = peak intensity of Method 1 ÷ peak intensity of Method 2.
Figure 2Venn diagram of the assigned glycans in Table 3. The number in the parenthesis indicates the number of assigned glycans in each ranking group. In = intensity of Method i in a particular peak. The average and standard deviation were calculated for the commonly assigned 15 glycans of Set A.